BioSpace News Archive

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the third quarter and year-to-date for the period ended September 30, 2020. “Navidea continues to build on its clinical

CooperCompanies announced that its Board of Directors elected Teresa S. Madden to the Board as an independent director, effective December 1, 2020.

Viveve Medical, Inc., a medical technology company focused on women’s intimate health, reported financial results for the quarter ended September 30, 2020, and will provide a corporate update.

Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today provides a business update and reports financial results for the quarter ended September 30, 2020. Management is hosting an earnings call today at 4:30 p.m. ET. The third quarter of 2020 was marked by meaningful corporate, financial and clinical progress. Highlights New

Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the third quarter ended September 30, 2020 and provided a business update. “Vaxcyte continues to make steady progress in executing on our business objectives

Berkeley Lights, Inc., a leader in Digital Cell Biology, reported financial results for the quarter ended September 30, 2020.

Conference call to discuss financial and operational results scheduled for Friday, November 13 at 8:30 a.m. U.S. Eastern Time

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a “fireside chat” presentation at the Jefferies Virtual London Healthcare Conference on Thursda

Increasing Placebo Responses in PTSD Drug Trials Raise Questions About Current Methods of Measuring or Analyzing PTSD Symptom Change Over Time The U.S. 21 st Century Cures Act Provides Direction on New Statistical Analyses Using Simulations Tonix Plans to Study TNX-102 SL in a New Phase 3 PTSD Trial in Kenya

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming Canaccord Genuity Virtual MedTech & Diagnostics Forum. Management is scheduled to present Thursday, November 19, 2020 at 2:30pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at www.t2bio